Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Fase 2a placebokontrolleret undersøgelse af VTX3232 alene eller i kombination med semaglutid ved fedme

9. september 2026 opdateret af: Zomagen Biosciences Ltd.

En fase 2a, multicenter, randomiseret, dobbeltblind, placebokontrolleret undersøgelse til evaluering af sikkerheden, tolerabiliteten, farmakokinetikken og farmakodynamikken af ​​VTX3232 alene eller i kombination med Semaglutid hos deltagere med fedme

This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in combination with semaglutide, or placebo in combination with semaglutide. The study consisted of a 30-day screening period, a 12-week double-blind treatment period, and a 30-day follow-up period. The maximum treatment duration was 12 weeks.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

175

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35235
        • 840005
    • California
      • Lake Forest, California, Forenede Stater, 92630
        • 840003
      • Long Beach, California, Forenede Stater, 90815
        • 840011
    • Florida
      • Largo, Florida, Forenede Stater, 33761
        • 840001
      • Ocoee, Florida, Forenede Stater, 34761
        • 840012
      • Port Orange, Florida, Forenede Stater, 32127
        • 840016
    • Kansas
      • Newton, Kansas, Forenede Stater, 67114
        • 840014
    • Louisiana
      • Marrero, Louisiana, Forenede Stater, 70072
        • 840015
      • Marrero, Louisiana, Forenede Stater, 70072
        • 840017
    • Texas
      • Austin, Texas, Forenede Stater, 78705
        • 840002
      • Dallas, Texas, Forenede Stater, 75230
        • 840006
      • San Antonio, Texas, Forenede Stater, 78229
        • 840013
      • San Antonio, Texas, Forenede Stater, 78229
        • 840018
      • Waco, Texas, Forenede Stater, 76710
        • 840010

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participants are male or female ≥ 18 years up to ≤ 80 years of age.
  • Ability to comply with study requirements.
  • BMI ≥ 30.0 to ≤ 42.0 kg/m2 at screening.
  • Stable body weight (± 5%) for at least 3 months prior to screening.
  • hs-CRP ≥ 2 mg/L at screening.
  • Hypertension or hyperlipidemia which are known to be associated with increased risk of cardiovascular events, if present, must be controlled with stable dose/therapy.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion Criteria:

  • Obesity induced by endocrinologic disorders, or diagnosed genetic or syndromic forms of obesity

  • Have any prior diagnosis of diabetes mellitus

  • Current participation (or within the last 3 months) in an organized weight reduction program.

  • History or presence of clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass [bariatric] surgery or restrictive bariatric surgery), or have an endoscopic and/or device-based therapy for obesity.

  • Clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult.

  • Use of any medication (e.g., GLP-1 agonists), nutritional supplement, or over the counter product for weight loss within the previous 6 months or during study participation, unless administered as a part of assigned study treatment in this study.

  • Receipt of the following medications:

    1. Any immunosuppressive biologic or targeted therapy within 90 days prior to Day 1.
    2. Use of anti-inflammatory medications within 30 days prior to Day 1
    3. Colchicine within 30 days prior to Day 1.
    4. Glucose-lowering agent(s) administered for conditions other than diabetes within 90 days before screening.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Participants received placebo orally once daily for 12 weeks and were followed for 30 days after the last dose.

Placebo

Eksperimentel: VTX3232 30 mg

Participants received VTX3232 30 milligrams (mg) orally once daily for 12 weeks and were followed for 30 days after the last dose.

VTX3232 30 mg

Aktiv komparator: Placebo + Semaglutide

Participants received placebo orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose.

Placebo in combination with semaglutide

Eksperimentel: VTX3232 30 mg + Semaglutide

Participants received VTX3232 30 mg orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose.

VTX3232 30 mg in combination with semaglutide

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)
Tidsramme: From the first dose of study treatment to Week 16

A TEAE was defined as any adverse event that occurred after initiation of study treatment or any pre-existing adverse event that worsened in severity following initiation of study treatment.

From the first dose of study treatment to Week 16

Sekundære resultatmål

Resultatmål
Tidsramme
Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (Hs-CRP) Level
Tidsramme: From baseline to Week 12
From baseline to Week 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Snehal Naik, PhD, Zomagen Biosciences Ltd.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. januar 2025

Primær færdiggørelse (Faktiske)

10. september 2025

Studieafslutning (Faktiske)

10. september 2025

Datoer for studieregistrering

Først indsendt

8. januar 2025

Først indsendt, der opfyldte QC-kriterier

8. januar 2025

Først opslået (Faktiske)

13. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • VTX3232-204
  • J7V-MC-EOBA (Anden identifikator: Eli Lilly and Company)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner